These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11165427)

  • 1. Toward less futile surgery in non-small cell lung cancer? A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography.
    van Tinteren H; Hoekstra OS; Smit EF; Verboom P; Boers M;
    Control Clin Trials; 2001 Feb; 22(1):89-98. PubMed ID: 11165427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.
    van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; Verboom P; van Mourik JC; Postmus PE; Boers M; Teule GJ
    Lancet; 2002 Apr; 359(9315):1388-93. PubMed ID: 11978336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
    Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
    Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
    Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
    Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approach.
    Verboom P; Herder GJ; Hoekstra OS; Smit EF; van den Bergh JH; van Velthoven PC; Grijseels EW
    Int J Technol Assess Health Care; 2002; 18(3):576-85. PubMed ID: 12391950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.
    Reed CE; Harpole DH; Posther KE; Woolson SL; Downey RJ; Meyers BF; Heelan RT; MacApinlac HA; Jung SH; Silvestri GA; Siegel BA; Rusch VW;
    J Thorac Cardiovasc Surg; 2003 Dec; 126(6):1943-51. PubMed ID: 14688710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer?
    Kozower BD; Meyers BF; Reed CE; Jones DR; Decker PA; Putnam JB
    Ann Thorac Surg; 2008 Apr; 85(4):1166-9; discussion 1169-70. PubMed ID: 18355490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
    Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals.
    Herder GJ; Verboom P; Smit EF; van Velthoven PC; van den Bergh JH; Colder CD; van Mansom I; van Mourik JC; Postmus PE; Teule GJ; Hoekstra OS
    Thorax; 2002 Jan; 57(1):11-4. PubMed ID: 11809983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
    Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
    Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
    Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)].
    Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
    Kaku Igaku; 1998 Jul; 35(6):395-404. PubMed ID: 9753918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.
    Nguyen VH; Peloquin S; Lacasse Y
    Can Respir J; 2005; 12(1):19-25. PubMed ID: 15776130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?
    Kernstine KH; Mclaughlin KA; Menda Y; Rossi NP; Kahn DJ; Bushnell DL; Graham MM; Brown CK; Madsen MT
    Ann Thorac Surg; 2002 Feb; 73(2):394-401; discussion 401-2. PubMed ID: 11845848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
    J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
    Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer. The Canadian Lung Oncology Group.
    Ann Thorac Surg; 2001 Feb; 71(2):425-33; discussion 433-4. PubMed ID: 11235682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical resection and long-term survival outcome for non-small cell lung cancer: a comparison of Victorian population-based studies spanning a decade.
    Wright GM; Thursfield VJ; Ball DL; Richardson GE; Irving L; Giles GG; Mitchell P
    Asia Pac J Clin Oncol; 2014 Mar; 10(1):75-9. PubMed ID: 24289256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.